




**Transcend Sarcoma**

30 John Bunn Mill, Bourneside Road, KT15 2JX

Charity number: 1208923



<https://www.transcendsarcoma.com/>



[transcendsarcoma@gmail.com](mailto:transcendsarcoma@gmail.com)



@transcendsarcoma

# Transcend Sarcoma

**ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 30 JUNE 2025**

**Charity registration number 1208923 (England and Wales)**

# TRANSCEND SARCOMA

## LEGAL AND ADMINISTRATIVE INFORMATION

---

|                                                                |                                                                                                                               |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| <b>Trustees who served during the year ending 30 June 2025</b> | Jack Holmes (Chair) - 24 June 2024 to 3 October 2024<br>Assad Rashid<br>Mark Holmes<br>Harry Fothergill<br>Rachel Louise Kapo |
| <b>Charity number (England and Wales)</b>                      | 1208923                                                                                                                       |
| <b>Legal structure</b>                                         | Charitable Incorporated Organisation ("the CIO")                                                                              |
| <b>Principal address</b>                                       | 30 John Bunn Mill, Bourneside Road, KT15 2JX                                                                                  |
| <b>Independent examiner</b>                                    | Bowdon Accounting Services Ltd<br>Bartle House, Oxford Court, Manchester M2 3WQ                                               |

# TRANSCEND SARCOMA

## CONTENTS

---

|                                                | <b>Page</b> |
|------------------------------------------------|-------------|
| <b>Trustees report</b>                         | <b>4</b>    |
| <b>Statement of trustees' responsibilities</b> | <b>11</b>   |
| <b>Independent examiner's report</b>           | <b>12</b>   |
| <b>Statement of financial activities</b>       | <b>14</b>   |
| <b>Balance sheet</b>                           | <b>15</b>   |
| <b>Notes to financial statements</b>           | <b>16</b>   |

# **TRANSCEND SARCOMA**

## **TRUSTEES' REPORT**

### **FOR THE YEAR ENDED 30 JUNE 2025**

---

The trustees present their annual report and financial statements for the year ended 30 June 2025. This is the charity's first annual report since its establishment in June 2024.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

#### **Objectives and activities**

The objects of the CIO are:

For the public benefit the relief of sickness and the preservation of health in particular by providing grants to fund medical research into Soft Tissue Sarcoma, specifically those Sarcomas caused by chromosomal translations, and by promoting and supporting the publication and dissemination of the useful results of such research.

#### **Public benefit**

The trustees confirm that they have complied with their duty under section 17 of the Charities Act 2011 to have due regard to the Charity Commission's guidance on public benefit when planning and undertaking the charity's activities.

# **TRANSCEND SARCOMA**

## **TRUSTEES' REPORT (CONTINUED)**

### **FOR THE YEAR ENDED 30 JUNE 2025**

---

#### **Achievements and Performance**

Transcend Sarcoma's founder and chair of trustees Jack Holmes was diagnosed with stage 4 CIC::DUX Sarcoma at the age of 33 in November 2023 – a rare type of Soft Tissue Sarcoma caused by a chromosomal translocation. Jack's treatment options were limited to extension of life plans as no targeted treatment exists for this type of Sarcoma. Jack spent significant time researching sarcoma and potential treatment developments, especially thanks to the support of the Sarcoma Pathology team at the Royal National Orthopaedic Hospital NHS Trust. Through this connection Jack was inspired to establish a charity dedicated to raising funds for research into translocation-driven sarcomas. This is when Transcend Sarcoma was born.

Jack sadly passed away on 3 October 2024, just 12 months after diagnosis but the work of Transcend Sarcoma continues, led by the remaining board of trustees.

The work of the charity is supported mainly through:

- Charity events (ticket sales).
- Merchandise sales.
- Donations received from external fundraisers.
- Gifts received from other donors.

Transcend Sarcoma is a voluntary-run charity, led by its board of trustees. The trustees are responsible for the overall management and control of the charity, meeting on a monthly basis and collectively making any major decisions. Day-to-day operations are managed by trustees, with support at specific fundraising events from volunteers from the wider Transcend Sarcoma community. Funds raised during this first year as a charity came from a number of different sources, including individual donations, small grants, and community fundraising activities. Events organised by Transcend Sarcoma during its first year took a number of different forms, reflecting a varied programme designed to engage the community and support its objectives. These included a Summer Festival featuring a Makers' Market alongside live music, an evening of opera held in York, and a live music event in Hoxton, London.

All events organised by Transcend Sarcoma aim to:

- Generate surplus funds, ensuring monies raised can fund the specific aims of the charity
- Raise awareness of Soft Tissue Sarcoma
- Build a community to support in future fundraising

## **Grant-making Policy**

The charity's primary activity is to award grants to support research into soft tissue sarcomas, particularly those caused by chromosomal translocations.

The trustees have established a formal grant-making policy to ensure that funds are applied effectively and in furtherance of the charity's objectives.

All grant applications are assessed by the board of trustees, who have ultimate responsibility for approving funding decisions. In making these decisions, the trustees may seek advice from qualified medical researchers and specialists in the field of sarcoma.

Applications are evaluated against defined criteria, including:

- the potential impact of the research project;
- the cost-effectiveness of the proposed use of funds; and
- the scope for future research and long-term benefit.

The trustees undertake appropriate due diligence on grant recipients and require that funds are used solely for agreed charitable purposes. Grants are typically awarded for specific research activities and may be subject to reporting requirements to monitor progress and outcomes.

All grant decisions are made at the discretion of the trustees and are formally documented.

During the year, the charity awarded its first research grant in accordance with this policy.

# **TRANSCEND SARCOMA**

## **TRUSTEES' REPORT (CONTINUED)**

### **FOR THE YEAR ENDED 30 JUNE 2025**

---

On 9<sup>th</sup> September 2024, Transcend Sarcoma made its first grant of £25,000 to University College London ("UCL") to support research to develop "targeted protein degradation drugs in translocation driven sarcomas", led by Dr Nischalan Pillay at the UCL Cancer Institute.

The research is focused on developing a first-of-its-kind targeted therapy for clear cell sarcoma (CCS) - one of the rarest and most challenging forms of the disease. This project is helping to lay the groundwork for a new treatment approach to degrade translocation cancer proteins.

The trustees are actively exploring additional research opportunities aligned with the charity's objectives and intend to continue supporting promising projects as suitable opportunities arise.

#### **Financial review**

Total income for the year was £86,725.91.

Total expenditure was £32,884.51.

This resulted in a net surplus of £53,841.40 for the year.

The principal sources of income were fundraising events, merchandise sales, supporter-led fundraising activities and donations from individuals.

#### **Going Concern**

The trustees consider that the charity has sufficient resources to continue in operational existence for the foreseeable future, given its positive cash position and low level of ongoing costs. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

#### **Reserves Policy**

The charity currently holds unrestricted reserves of £53,841.40.

As a voluntary-run organisation with minimal overhead costs, the trustees do not consider it necessary to maintain reserves based on a fixed number of months of operating expenditure.

Instead, the trustees aim to retain sufficient reserves to:

- support future grant-making commitments aligned with the charity's objectives;  
and
- provide a modest working capital buffer to meet short-term operational needs.

The trustees review the level of reserves on an ongoing basis to ensure that funds are applied effectively in furtherance of the charity's aims.

# **TRANSCEND SARCOMA**

## **TRUSTEES' REPORT (CONTINUED)**

### **FOR THE YEAR ENDED 30 JUNE 2025**

---

#### **Structure, governance and management**

A Board of Trustees of up to five members meet regularly to administer the Charity.

The charity's constitution was adopted on 24<sup>th</sup> June 2024.

New trustees would be appointed in accordance with the governing document, though no changes to the board have taken place to date. No external person or organisation has the power to appoint trustees.

The following Trustees were reimbursed for expenses incurred in the course of their duties for the charity:

- Rachel Kapo - £1,575.55
- Mark Holmes - £189.72

No Trustee received any remuneration or other benefits from the charity during the year. No expenses were reimbursed to any other Trustees.

The charity has a policy in place to manage conflicts of interest. Trustees are required to declare any potential conflicts and, where appropriate, withdraw from decision-making. No conflicts of interest were identified during the year.

The trustees who served during the year and up to the date of signature of the financial statements were:

Jack Holmes (Chair) - 01 July 2024 – 3 October 2024

Assad Rashid

Mark Holmes

Harry Fothergill

Rachel Louise Kapo

The trustees' report was approved by the Board of Trustees

A handwritten signature in black ink, appearing to be 'AR' or similar, enclosed within a circular scribble.

Assad Rashid, ACA, Trustee

Date: 17/04/2026

# **TRANSCEND SARCOMA**

## **STATEMENT OF TRUSTEES' RESPONSIBILITIES**

### **FOR THE YEAR ENDED 30 JUNE 2025**

---

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales required the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that year.

In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any materials departures disclosed and explained in the financial statements; and
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**TRANSCEND SARCOMA**

**INDEPENDENT EXAMINER'S REPORT**

**TO THE TRUSTEES OF TRANSCEND SARCOMA**

---

**Report to the trustees/  
members of**

Transcend Sarcoma

**On accounts for the  
year ended**

30/06/2025

**Charity  
no (if any)**

1208923

---

I report to the trustees on my examination of the accounts of the above charity ("the Trust") for the year ended 30/06/2025.

**Responsibilities and  
basis of report**

As the charity trustees of the Trust, you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ("the Act").

I report in respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent examiner's  
statement

I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination which gives me cause to believe that in, any material respect:

- accounting records were not kept in accordance with section 130 of the Act or
- the accounts do not accord with the accounting records

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in order to enable a proper understanding of the accounts to be reached.

**Signed:**



**Date:** 27/04/2026

**Name:**

Adeel Sahi

**Relevant professional  
qualification(s) or body  
(if any):**

ACCA

**Address:**

Bowdon Accounting Services Ltd

Bartle House, Oxford Court

Manchester M2 3WQ

## TRANSCEND SARCOMA

### STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2025

---

#### STATEMENT OF FINANCIAL ACTIVITIES

#### INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2025

|                                      | Unrestricted Funds<br>30 June 2025<br>£ | Total<br>30 June 2025<br>£ |
|--------------------------------------|-----------------------------------------|----------------------------|
| <b>Income from:</b>                  |                                         |                            |
| Donations and gifts                  | 73,849.89                               | 73,849.89                  |
| Fundraising Events and Merchandise   | 12,876.02                               | 12,876.02                  |
| <b>Total income</b>                  | <b>86,725.91</b>                        | <b>86,725.91</b>           |
| <b>Expenditure on:</b>               |                                         |                            |
| Raising funds                        | 7,884.51                                | 7,884.51                   |
| Charitable activities (grants)       | 25,000.00                               | 25,000.00                  |
| <b>Total expenditure</b>             | <b>32,884.51</b>                        | <b>32,884.51</b>           |
| <b>Net movement in funds</b>         | <b>53,841.40</b>                        | <b>53,841.40</b>           |
| <b>Fund balances brought forward</b> | <b>–</b>                                | <b>–</b>                   |
| <b>Fund balances carried forward</b> | <b>53,841.40</b>                        | <b>53,841.40</b>           |

## TRANSCEND SARCOMA

## **BALANCE SHEET**

### **AS AT 30 JUNE 2025**

---

#### **BALANCE SHEET**

**AS AT 30 JUNE 2025**

|                                                       | <b>30 June 2025</b> |
|-------------------------------------------------------|---------------------|
|                                                       | <b>£</b>            |
| <b>Current assets</b>                                 |                     |
| Cash at bank and in hand                              | 53,841.40           |
| <b>Total assets</b>                                   | 53,841.40           |
| <b>Creditors: amounts falling due within one year</b> | –                   |
| <b>Net assets</b>                                     | 53,841.40           |
| <b>Funds</b>                                          |                     |
| Unrestricted funds                                    | 53,841.40           |

The financial statements were approved by the trustees on:



Assad Rashid, ACA, Trustee

Date: 17/04/2026

# **TRANSCEND SARCOMA**

## **NOTES TO THE FINANCIAL STATEMENTS**

### **FOR THE YEAR ENDED 30 JUNE 2025**

---

#### **1. Accounting policies**

##### **Basis of preparation**

The financial statements have been prepared under the historical cost convention and in accordance with the Charities Act 2011, the Charities (Accounts and Reports) Regulations 2008 and the Charities Statement of Recommended Practice (SORP) (FRS 102) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

The charity constitutes a public benefit entity as defined by FRS 102.

---

##### **Going concern**

The trustees consider that the charity has sufficient resources to continue in operational existence for the foreseeable future. Accordingly, the financial statements have been prepared on a going concern basis.

---

##### **Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.

All funds held during the year were unrestricted.

---

# TRANSCEND SARCOMA

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2025

---

#### **Income recognition**

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income comprises donations, fundraising events and merchandise sales.

All income received during the year was unrestricted.

---

#### **Expenditure recognition**

Expenditure is recognised on an accruals basis as a liability is incurred. Expenditure includes VAT which cannot be recovered and is reported as part of the expenditure to which it relates.

Expenditure is classified under the following headings:

- **Raising funds**, which includes costs incurred in generating voluntary income
  - **Charitable activities**, which includes grants awarded and related costs
- 

#### **Grants payable**

Grants payable are recognised in the financial statements when the trustees have made a formal commitment to make the grant and this has been communicated to the recipient.

---

#### **Cash and cash equivalents**

Cash and cash equivalents include cash at bank and in hand.

---

# TRANSCEND SARCOMA

## NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

### FOR THE YEAR ENDED 30 JUNE 2025

---

#### 2. Income

|                                    | £                |
|------------------------------------|------------------|
| Donations and gifts                | 73,849.89        |
| Fundraising events and merchandise | 12,876.02        |
| <b>Total income</b>                | <b>86,725.91</b> |

All income was derived from activities within the United Kingdom and relates to unrestricted funds.

---

#### 3. Expenditure

|                                | £                |
|--------------------------------|------------------|
| Raising funds                  | 7,884.51         |
| Charitable activities (grants) | 25,000.00        |
| <b>Total expenditure</b>       | <b>32,884.51</b> |

---

#### 4. Grants payable

During the year, the charity awarded a grant of £25,000 to University College London to support research into translocation-driven sarcomas.

---

#### 5. Trustees' remuneration and expenses

The following Trustees were reimbursed for expenses incurred in the course of their duties for the charity:

- Rachel Kapo - £1,575.55
- Mark Holmes - £189.72

No Trustee received any remuneration or other benefits from the charity during the year. No expenses were reimbursed to any other Trustees.

---

## **6. Related party transactions**

There were no related party transactions during the year.